Therapeutic plasma exchange in children with acute demyelination
Kids are not small adults!
Citation Manager Formats
Make Comment
See Comments

This article requires a subscription to view the full text. If you have a subscription you may use the login form below to view the article. Access to this article can also be purchased.
The discovery of specific biomarkers signaling antibody-related etiologies for severe CNS inflammatory disease has led to a marked change in diagnostic and treatment practices related to these disorders. In the pediatric population, more often than not, neuroinflammation may lead to severe clinical manifestations, including bilateral, severe optic neuritis with total visual loss or transverse myelitis with flaccid paresis of all extremities. While high-dose pulse methylprednisolone is used with benefit in the majority of children,1 some patients do not respond to this therapy. Importantly, some individuals with antibody-mediated neuroinflammatory disorder such as aquaporin-4 (AQP-4)–related disease (neuromyelitis optica spectrum disorder) may even experience irreversible motor and visual disability after the first event.2 Whether this disability can be prevented by early and aggressive acute therapy has been of interest to the clinical community, because studies in adult populations with neuroinflammatory disease suggest that greater benefit is associated with earlier use of therapeutic plasma exchange (TPE).3 Concomitant with this has been the rise of the use of TPE in pediatric neuroinflammatory diseases, but to date, reports have been limited to smaller case series.4 Of importance, knowledge about the timing of TPE after acute presentation of neuroinflammation in youth is limited. Clinicians are therefore faced with the following unanswered questions when caring for an acutely ill child: Should I escalate therapy, and when? How late is too late? How safe is TPE in this population?
Footnotes
Go to Neurology.org/N for full disclosures. Funding information and disclosures deemed relevant by the authors, if any, are provided at the end of the editorial.
See page 961
- © 2019 American Academy of Neurology
AAN Members
We have changed the login procedure to improve access between AAN.com and the Neurology journals. If you are experiencing issues, please log out of AAN.com and clear history and cookies. (For instructions by browser, please click the instruction pages below). After clearing, choose preferred Journal and select login for AAN Members. You will be redirected to a login page where you can log in with your AAN ID number and password. When you are returned to the Journal, your name should appear at the top right of the page.
AAN Non-Member Subscribers
Purchase access
For assistance, please contact:
AAN Members (800) 879-1960 or (612) 928-6000 (International)
Non-AAN Member subscribers (800) 638-3030 or (301) 223-2300 option 3, select 1 (international)
Sign Up
Information on how to subscribe to Neurology and Neurology: Clinical Practice can be found here
Purchase
Individual access to articles is available through the Add to Cart option on the article page. Access for 1 day (from the computer you are currently using) is US$ 39.00. Pay-per-view content is for the use of the payee only, and content may not be further distributed by print or electronic means. The payee may view, download, and/or print the article for his/her personal, scholarly, research, and educational use. Distributing copies (electronic or otherwise) of the article is not allowed.
Disputes & Debates: Rapid online correspondence
REQUIREMENTS
If you are uploading a letter concerning an article:
You must have updated your disclosures within six months: http://submit.neurology.org
Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.
If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.
Submission specifications:
- Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
- Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
- Submit only on articles published within 6 months of issue date.
- Do not be redundant. Read any comments already posted on the article prior to submission.
- Submitted comments are subject to editing and editor review prior to posting.